---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-25-000028"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:36:52.315605+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vistagen updates fasedienol Phase 3 timelines: PALISADE-3 data Q4 2025, PALISADE-4 H1 2026

## Summary
- PALISADE-3 topline data remains on track for Q4 2025; PALISADE-4 now expected in H1 2026.
- Positive PALISADE-2 results (2023) plus success in either PALISADE-3 or -4 could support NDA submission.
- Protocol enhancements include site training, surveillance, and subject selection to replicate PALISADE-2 success.
- CEO cites strong patient/physician enthusiasm and growing unmet need in social anxiety disorder.

## SEC filing metadata
- accession: 0001411685-25-000028
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000028/0001411685-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000028/vtgn-20250602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-25-000028
- JSON: https://secwatch.observer/filing/0001411685-25-000028.json
- Plain text: https://secwatch.observer/filing/0001411685-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.